Reuters logo
8 months ago
BRIEF-Progenics Pharma says 190 of 450 patients enrolled in phase 3 SPECT/CT imaging agent trial
December 22, 2016 / 9:34 PM / 8 months ago

BRIEF-Progenics Pharma says 190 of 450 patients enrolled in phase 3 SPECT/CT imaging agent trial

Dec 22 (Reuters) - Progenics Pharmaceuticals Inc :

* Progenics Pharmaceuticals Inc says approximately 190 of a planned 450 patients have been enrolled in trial to date

* Progenics Pharmaceuticals announces independent committee's positive recommendation for continuation of phase 3 clinical trial of SPECT/CT imaging agent 1404

* Progenics Pharmaceuticals announces independent committee's positive recommendation for continuation of phase 3 clinical trial of SPECT/CT imaging agent 1404 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below